Results 51 to 60 of about 39,159 (175)

DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain

Viruses
The continuous pharmacological advances in antiretroviral treatment (ART) and the increasing understanding of HIV drug resistance has led to a change in the paradigm of ART optimization in the setting of the viral suppression of treatment-experienced ...
Sergio Sequera-Arquelladas, Carmen Hidalgo-Tenorio, Luis López-Cortés, Alicia Gutiérrez, Jesús Santos, Francisco Téllez, Mohamed Omar, Sergio Ferra-Murcia, Elisa Fernández, Rosario Javier, Coral García-Vallecillos, Juan Pasquau   +11 more
doaj   +1 more source

Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis

Virology Journal, 2009
Background Currently, there is no evidence on the combination of lamivudine and thymosin alpha-1 on chronic hepatitis B patients. The aim of this study was to compare the effect of lamivudine monotherapy with that of lamivudine and thymosin alpha-1 ...
Yang Jin, Chen En-Qiang, Zhang Yuan-Yuan, Duan Yu-Rong, Tang Hong   +4 more
doaj   +1 more source

Real-World Experience of Telbivudine and Lamivudine as Antiviral Prophylaxis for Chemotherapy-Related Hepatitis B Reactivation

Indonesian Journal of Cancer, 2021
Background: There is currently no data regarding the efficacy of prophylactic telbivudine in hepatitis B patients undergoing chemotherapy. This study aims to describe the results of preemptive telbivudine and lamivudine to prevent chemotherapy-related ...
Lianda Siregar, Imelda Maria Loho, Agus Sudiro Waspodo, Siti Nadliroh, Rahmanandhika Swadari, Rizka Andalusia, Leovinna Widjaja   +6 more
doaj   +1 more source

HIV viral suppression in children and adolescents who transitioned from ritonavir‐boosted lopinavir‐ to dolutegravir‐based antiretroviral therapy in Lesotho

HIV Medicine, EarlyView.
Abstract Objectives Children and adolescents living with HIV previously taking ritonavir‐boosted lopinavir (LPV/r)‐based antiretroviral therapy (ART) have been programmatically transitioned to dolutegravir (DTG)‐based regimens in many country programs.
Jacob Blankenberger, Teresa L. F. Steffy, Tristan Lee, Thithili Makhesi, Meenakshi Bakaya, Akash Devendra, Pheello Mothepu, Lipontso Motaboli, Nadine Tschumi, Anna Klicpera, Tapiwa Tarumbiswa, Frédérique Chammartin, Lineo K. Thahane, Niklaus D. Labhardt, Jennifer A. Brown   +14 more
wiley   +1 more source

Gaps in diabetes care among people living with HIV and hypertension in Botswana: A cross‐sectional analysis of the InterCARE study

HIV Medicine, EarlyView.
Abstract Objectives Data on diabetes screening and monitoring, within HIV care programmes in sub‐Saharan Africa, remain limited. This study describes the quality of diabetes screening and management among people living with HIV with comorbid hypertension receiving care at facilities participating in the InterCARE trial in Botswana. Methods We conducted
Onkabetse Julia Molefe‐Baikai, Tshepo B. Leeme, Moagedi K. Mawi, Kago Kebotsamang, Thato Moshomo, Edwin Mogaetsho, Tendani Gaolathe, Kesaobaka Molebatsi, Matlhogonolo Kelepile, Keonayang Kgotlaetsile, Pooja Gala, Duolao Wang, Shabbar Jaffar, Laura M. Bogart, Lisa R. Hirschhorn, Mosepele Mosepele   +15 more
wiley   +1 more source

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens [PDF]

, 2010
Background During stavudine phase-out plan in developing countries, tenofovir is used to substitute stavudine. However, knowledge regarding whether there is any difference of the frequency of renal injury between tenofovir/lamivudine/efavirenz and ...
Lueangniyomkul Aroon, Aroon Lueangniyomkul, Tantanathip Preecha, Anongnuch Narkksoksung, Mankatitham Wiroj, Sungkanuparph Somnuek, Somnuek Sungkanuparph, Samruay Nilkamhang, Nilkamhang Samruay, Wiroj Mankatitham, Prasithsirikul Wisit, Manosuthi Weerawat, Weerawat Manosuthi, Preecha Tantanathip, Suntisuklappon Busakorn, Busakorn Suntisuklappon, Wisit Prasithsirikul, Narkksoksung Anongnuch   +17 more
core   +1 more source

Efficacy and safety of lamivudine treatment in late pregnancy with high HBV DNA: a perspective for mother and infants

Journal of Infection in Developing Countries, 2011
Introduction: Perinatal transmission - from mother to fetus - is one of the main transmission routes of chronic hepatitis B (CHB) infection. Lamivudine therapy has been reported to prevent the replication of hepatitis B virus (HBV) in pregnant women ...
Sükran Köse, Melda Türken, İlker Devrim, Cüneyt Taner   +3 more
doaj   +1 more source

Feasibility and clinical outcomes of routine point‐of‐care screening for opportunistic infections among people with advanced HIV disease in Guyana

HIV Medicine, EarlyView.
Abstract Objectives We evaluated the feasibility and outcomes of implementing comprehensive Point‐of‐care (POC) opportunistic infections (OIs) screening among people with Advanced HIV disease (AHD) in Guyana. Methods We conducted a prospective multicentre cohort study across seven sites between February 2024 and March 2025.
Antonio Camiro‐Zúñiga, Tariq Jagnarine, Divya Shivdas, Lakshmi Narain, Kwesi Vanccoten, Kampta Prashad, Abiola Jacobs, Quacy Grant, Mallika Mootoo, Narissa Lawerence, Suzanne Siebs, Escalada Rainier, Omar Sued, Freddy Perez   +13 more
wiley   +1 more source

Longitudinal changes in readily available inflammatory markers before and after switching to integrase inhibitor‐based antiretroviral therapy in Virologically suppressed people living with HIV: A Nationwide real‐world cohort study

HIV Medicine, EarlyView.
Abstract Background Persistent immune activation and systemic inflammation remain key features of chronic HIV infection despite sustained virological suppression under antiretroviral therapy (ART), contributing to excess non‐AIDS morbidity and mortality.
Stelios Assimakopoulos, Achilleas Stamoulopoulos, Mina Psichogiou, Varvara Vasalou, Vasileios Papastamopoulos, Antonis Papadopoulos, Georgios Adamis, Maria Chini, Simeon Metallidis, Georgios Loizos, Lydia Leonidou, Helen Sambatakou, Markos Marangos, Diamantis Kofteridis, Giota Touloumi, on behalf of AMACS, G. Adamis, M. Chini, G. Chrysos, M. Marangos, O. Katsarou, D. Kofteridis, S. Metallidis, P. Panagopoulos, N. Pantazis, A. Papadopoulos, V. Paprizos, V. Papastamopoulos, M. Psichogiou, H. Sambatakou, NV. Sipsas, G. Touloumi, G. Touloumi, N. Pantazis, C. Thomadakis, A Stamoulopoulos, A Papadopoulos, A Antoniadou, C Protopapas, D Kavatha, G Chrysos, T Nitsotolis, M Psichogiou, E Mastrogianni, G Adamis, M Astriti, MN Marangos, L Leonidou, O Katsarou, A Kouramba, NV Sipsas, A Kontos, D Basoulis, M Chini, G Tsekes, N Mangafas, S Metallidis, O Tsachouridou, Τ Chrysanthidis, V Paparizos, V Vasalou, S Kourkounti, H Sambatakou, V Papastamopoulos, G Lourida, P Panagopoulos, V Petrakis, D Kofteridis, K Alexakis, V Malikidis, H Gogos, M Psichogiou   +71 more
wiley   +1 more source

Dosing HIV integrase inhibitors with enzyme inducers: Convenience vs. control?

British Journal of Clinical Pharmacology, EarlyView.
Catia Marzolini, Saye Khoo
wiley   +1 more source